Philochem is open to partnerships that are in line with the company’s corporate strategy to continue the development of its preclinical and clinical programs and to develop and advance its technology platforms.
Philochem offers collaborations based on its proprietary small molecule ligands for pharmacodelivery and will selectively choose to partner with companies that have therapeutic expertise in relevant disease areas and a significant commitment to the development and commercialization of targeted drugs.
In addition, Philochem offers attractive fee-for-service collaborations using the following platform technologies:
Collaboration on DNA-Encoded Chemical Libraries
Philochem has pioneered the development of the DNA-Encoded Chemical Library (DECL) technology, which opens new possibilities for drug discovery in a fast and cost-effective way. Philochem owns proprietary technologies and large DNA-encoded chemical libraries containing more than one billion compounds.
We offer flexible collaboration structures, adjusted to the requirements of the partner, for the screening of binders against few or several targets of choice. For more information, please visit: Enabling Technologies: 1. DNA-Encoded Chemical Libraries
For collaboration opportunities, partnerships, or licensing agreements, please contact:
Head of Human Resources
Carolina graduated with a degree in Law at the University of Siena. From 1996 to 1998 she was a trainee at a legal office. From 1998 to 2008 she was Branch Manager at Manpower S.p.A., dealing with Human Resources services. Since 2008 she is the Human Resources Manager of Philogen
Frederik graduated in Pharmaceutical Sciences at ETH Zürich and performed an industrial Ph.D. at Philochem in which he focused on the generation and characterization of novel fully-human monoclonal antibodies. Frederik is author of several peer-reviewed publications in international scientific journals and joined the Business Development team at Philochem in 2023.
Collaborations on antibodies and cyclic peptides
Philochem has constructed and validated antibody phage libraries comprising more than 100 billion members. These proprietary libraries enable the fast and cost-effective isolation of human monoclonal antibodies against virtually any antigen of interest. Philochem also owns proprietary phage libraries of short cyclic peptides comprising more than 100 billion members.
We offer flexible collaboration structures, adjusted to the requirements of the partner, for the screening of binders against one or more targets of choice. For more information, please visit: Library Technologies: Antibody Phage Libraries
A wealth of partnerships validate our approach and science
The Philogen Group has signed collaboration and/or licensing agreements with large pharmaceutical companies including AbbVie, Bayer, BMS, Boehringer Ingelheim, Bracco, Celgene (a subsidiary of Bristol-Myers Squibb), IBSA, Janssen Biotech, Inc. (a Johnson & Johnson company), MedImmune (a wholly owned subsidiary of AstraZeneca), Merck-Serono, MSD, Novartis, Pfizer, Schering, Servier, and Sun Pharma
Our collaboration agreements with academic institutions include ETH Zurich, Scripps Research, The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), University of Zurich and Wyss Translational Center Zurich